Actimed Therapeutics Expands Intellectual Property Portfolio

• Two new composition of matter patents granted in the US and Europe
• Patents provide protection relating to lead compound S-pindolol benzoate (ACM-001.1), significantly strengthening company’s intellectual property portfolio

London, UK – 6 February 2025. Actimed Therapeutics, a UK based clinical stage speciality pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces today that it has received new patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO).

Both patents provide protection relating to ACM-001.1 (S-pindolol benzoate), an anti-catabolic and pro-anabolic transforming agent (ACTA) with a multifunctional effect on key pharmacological targets relevant for cancer cachexia and other muscle wasting disorders.

• European Patent EP 4132909 B covers a pharmaceutically acceptable salt of: (i) S-pindolol; and (ii) benzoic acid.  
• US Patent US 12,109,192 B covers the two preferred crystalline forms of S-pindolol benzoate. 

Robin Bhattacherjee, Actimed CEO, commented: “I am delighted to confirm the grant of these two key patents relating to ACM001.1, which provide robust intellectual property supporting our lead asset. This is crucial as we focus on advancing ACM001.1 into late-stage clinical development for cancer cachexia. The impact of cancer cachexia on patients and the urgent need for new treatments has become increasingly apparent, and we continue to press ahead with our plans to bring our potential new therapy to the many cancer patients suffering from this devastating condition.”